Andre C. Schuh
Princess Margaret Cancer Centre
10 Papers
45 Citations
Andre C. Schuh is an academic researcher from Princess Margaret Cancer Centre. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 8, co-authored 10 publications. Previous affiliations of Andre C. Schuh include University of Toronto.
Chat about Author
Papers
Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia
Liran I. Shlush,Sasan Zandi,Amanda Mitchell,Weihsu Claire Chen,Joseph M. Brandwein,Vikas Gupta,James A. Kennedy,Aaron D. Schimmer,Andre C. Schuh,Karen W.L. Yee,Jessica McLeod,Monica Doedens,Jessie J. F. Medeiros,Rene Marke,Hyeoung Joon Kim,Kwon Lee,John Douglas Mcpherson,Thomas J. Hudson,Andrew M.K. Brown,Fouad Yousif,Quang M. Trinh,Lincoln Stein,Mark D. Minden,Jean C.Y. Wang,John E. Dick +24 more
TL;DR: Highly purified haematopoietic stem cells, progenitor and mature cell fractions from the blood of AML patients were found to contain recurrent DNMT3A mutations at high allele frequency, but without coincident NPM1 mutations (NPM1c) present in AML blasts.
Treatment outcomes following leukemic transformation in Philadelphia-negative myeloproliferative neoplasms.
James A. Kennedy,Eshetu G. Atenafu,Hans A. Messner,Kenneth J. Craddock,Joseph M. Brandwein,Jeffrey H. Lipton,Mark D. Minden,Aaron D. Schimmer,Andre C. Schuh,Karen W.L. Yee,Vikas Gupta +10 more
TL;DR: Induction chemotherapy followed by HCT has the potential for long-term disease control in select patients with LT preceded by a MPN, and survival of patients posttransplant was significantly improved.
131
Treatment of elderly patients with acute lymphoblastic leukaemia using a paediatric-based protocol.
Marc Poch Martell,Eshetu G. Atenafu,Mark D. Minden,Andre C. Schuh,Karen W.L. Yee,Aaron D. Schimmer,Vikas Gupta,Joseph M. Brandwein +7 more
TL;DR: Administration of this modified paediatric‐based protocol is feasible and active for elderly patients with ALL, and survival is superior to most previously reported series in this age group, but remains worse compared to younger patients.
30
The prognostic impact of FLT3-ITD and NPM1 mutations in patients with relapsed acute myeloid leukemia and intermediate-risk cytogenetics.
J How,Jenna Sykes,Mark D. Minden,Vikas Gupta,Karen W.L. Yee,Aaron D. Schimmer,Andre C. Schuh,Suzanne Kamel-Reid,Joseph M. Brandwein +8 more
TL;DR: In intermediate-risk karyotype AML patients receiving reinduction, CR1 duration remains the most important predictor of OS at relapse; FLT3-ITD and NPM1 status are not independent predictors of survival.
•Journal Article
Treatment of older patients with acute myeloid leukemia (AML): a Canadian consensus
Joseph M. Brandwein,Michelle Geddes,Jeannine Kassis,Andrea Kew,Brian Leber,Thomas J. Nevill,Mitchell Sabloff,Irwindeep Sandhu,Andre C. Schuh,John M. Storring,John Ashkenas +10 more
TL;DR: It is recognized that cytogenetics and molecular markers are major biologic determinants of treatment outcomes in the older population, both during induction therapy and following HSCT.
18